Yonhap Infomax NewsSamsung Bioepis and EpisNexLab partner with G2GBio to develop long-acting obesity treatments using microsphere-based drug delivery technology, while Samsung Epis Holdings invests 20 billion won in convertible bonds as part of open innovation strategy to expand into comprehensive bio company.
#YonhapInfomax #SamsungBioepis #ObesityTreatment #G2GBio #DrugDeliveryTechnology #Semaglutide #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=110037
#YonhapInfomax #SamsungBioepis #ObesityTreatment #G2GBio #DrugDeliveryTechnology #Semaglutide #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=110037
Samsung Bioepis, EpisNexLab Partner with G2GBio to Develop Obesity Treatment
Samsung Bioepis and EpisNexLab partner with G2GBio to develop long-acting obesity treatments using microsphere-based drug delivery technology, while Samsung Epis Holdings invests 20 billion won in convertible bonds as part of open innovation strategy to expand into comprehensive bio company.